Vimarsana
Biggest News Aggregation in the World

Page 4 - John Bluth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Bluth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Bluth Today - Breaking & Trending Today

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 06, 2023 -- BioCryst Pharmaceuticals, Inc. today announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired... | June 6, 2023

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile - Vimarsana News

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

RESEARCH TRIANGLE PARK, N.C., May 22, 2023 -- BioCryst Pharmaceuticals, Inc. today announced that the Public Health Institute of Chile has granted marketing authorization for oral, once-daily... | May 22, 2023

BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript - Vimarsana News

BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript

BCRX earnings call for the period ending March 31, 2023.

Source: fool.com
BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat) - Vimarsana News

BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., April 27, 2023 -- BioCryst Pharmaceuticals, Inc. today announced new data from the APeX-S clinical trial, which evaluated oral, once-daily ORLADEYO® for the... | April 27, 2023

BioCryst Celebrates Bob Ingram's Contributions to the - Vimarsana News

BioCryst Celebrates Bob Ingram's Contributions to the

RESEARCH TRIANGLE PARK, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today acknowledged the many contributions...